Several publications document the occurrence of prolonged or late-onset symptoms beyond 3weeks after the first clinical manifestations of SARS-COV2 infection. Thesemanifestations may be related to thromboembolic or inflammatory events or othermechanisms that are not yet well understood. The psychosomatic origin secondary topsychiatric disorders prior to the infection or in reaction to it is also to be evoked.The identification of the clinical manifestations observed, and their clinical andparaclinical evolution are essential to better understand the natural evolution ofCOVID-19, to specify the physiopathological mechanisms and to identify potential avenuesof management for the patients. In addition, the impact of COVID-19 infection on primarycare visits is not known. In general practice, these patients benefit from explorationsand even diagnoses that may explain the persistence of symptoms (autoimmune diseases,thrombosis, somatoform disorders, hyperventilation syndrome, etc.).The objective of the COCO_Vi_LATE project is to carry out a cross-sectional study ofpatients presenting persistent and/or recurrent symptoms after an infection withSARS-COV-2 who will be compared to individuals with a short form of infection withCOVID-19
Not Provided
Other: Questionnaire
Questionnaire SSD-12 and EQ5D5L
Other: medical consultation
Medical consultation during the visit with data collection
Inclusion Criteria:
A- For COVID cases:
1. Consultation in a city doctor's office
2. Positive SARS-CoV-2 RT-PCR result OR positive SARS-CoV-2 serology
3. Patient symptomatic or not
Definition of symptomatic :
1. Anosmia
2. OR CT scan suggestive of COVID 19
3. OR ≥ 2 symptoms contemporaneous with virologic sampling among: asthenia, cough,
dyspnea, fever, myalgias, dysgeusia, diarrhea AND not present previously at
diagnosis
B-. For NON COVID cases:
1. Consultation in a city doctor's office
2. No known COVID+ serology
3. No known RT- PCR SARS-CoV-2
4. No clinical suspicion of COVID-19 infection
Exclusion Criteria:
1. Minor patient
2. Refusal to participate
3. Patient under protection
4. Patient requiring hospitalization for COVID-19 (excluding non-emergency
hospitalization)
5. Patient consulted for the following reason only: treatment monitoring, treatment
renewal or certificate, hospital discharge
CH Tourcoing
Tourcoing, France
Olivier ROBINEAU, MD
0320694949
orobineau@ch-tourcoing.fr
Solange TREHOUX, PhD
0320694280
strehoux@ch-tourcoing.fr